Skip to content
Shuttingdown

Apogee Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SAN FRANCISCO · CA

No longer listed

High confidence (85%)

Updated Oct 19, 2026, 12:03 AM

What is happening

Derived by rule set status-rules-2026.09.7

The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

Latest material event: Apogee Therapeutics, Inc. deregistered its securities (Sep 14, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Apogee Therapeutics, Inc. deregistered its securities

    Sep 14, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 ef20081882_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 15     CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.   Commission File Number 001-41740     APOGEE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     c/o AbbVie, Inc. 1 North Waukegan Road North Chicago, Illinois 60064 (847) 932-7900 (…”

  2. Apogee Therapeutics, Inc. received a delisting notice from its exchange

    Sep 3, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures in the Introductory Note are incorporated herein by reference. On September 3, 2026, the Company (i) notified the Nasdaq Global Market ( Nasdaq ) of the consummation of the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) maintain the halt in trading of Company Common Stock, which was effective following the closing of af…”

  3. Apogee Therapeutics, Inc. was delisted from its exchange

    Sep 3, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001974640 Apogee Therapeutics, Inc. 001-41740 221 Crescent St Building 17, Suite 102b Waltham MA MASSACHUSETTS 02453 (650) 394-5230 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-09-03”

Company information

Founded
—
Employees (estimate)
—
Industry
Biological Products, (No Diagnostic Substances)
Subindustry
—
Listing
SEC lists the ticker APGE on Nasdaq.
SEC CIK
0001974640
Website
—
LinkedIn
—
Headquarters
SAN FRANCISCO, CA
Also known as
Apogee Therapeutics, LLC
Legal entities
Apogee Therapeutics, Inc., Apogee Therapeutics, Inc.

Sources

Every material source used to build this profile.

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 ef20081882_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 15     CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.   Commission File Number 001-41740     APOGEE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     c/o AbbVie, Inc. 1 North Waukegan Road North Chicago, Illinois 60064 (847) 932-7900 (…
    View source record

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Apogee Therapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — SAN FRANCISCO, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001974640 Apogee Therapeutics, Inc. 001-41740 221 Crescent St Building 17, Suite 102b Waltham MA MASSACHUSETTS 02453 (650) 394-5230 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-09-03
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures in the Introductory Note are incorporated herein by reference. On September 3, 2026, the Company (i) notified the Nasdaq Global Market ( Nasdaq ) of the consummation of the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) maintain the halt in trading of Company Common Stock, which was effective following the closing of af…
    View source record

Status history

Every derived status, with the rule that produced it.

  • NO_LONGER_LISTED → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 20, 2026, 12:14 AM

    The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

  • DISTRESS_SIGNAL → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 18, 2026, 01:31 AM

    The company stopped being publicly listed. A listing ends on the close of a merger as surely as it ends in failure, and the filing does not say which happened here.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:15 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 13, 2026, 12:05 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 02:39 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.